These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32250474)

  • 1. Effects of overweight and underweight on the treatment outcomes of rheumatoid arthritis patients treated with biological drugs: A retrospective observational descriptive study.
    Hirai T; Funaki A; Murakami K; Hanada K; Itoh T
    J Clin Pharm Ther; 2020 Aug; 45(4):666-673. PubMed ID: 32250474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
    Kim SK; Choe JY; Park SH; Lee H
    Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study.
    Yoshida K; Radner H; Mjaavatten MD; Greenberg JD; Kavanaugh A; Kishimoto M; Matsui K; Okada M; Reed G; Saeki Y; Tohma S; Kremer J; Solomon DH
    J Rheumatol; 2015 Dec; 42(12):2238-46. PubMed ID: 26523025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis.
    Sandberg ME; Bengtsson C; Källberg H; Wesley A; Klareskog L; Alfredsson L; Saevarsdottir S
    Ann Rheum Dis; 2014 Nov; 73(11):2029-33. PubMed ID: 24818635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack association of body mass index with disease activity composites of rheumatoid arthritis in Korean population: cross-sectional observation.
    Choe JY; Bae J; Lee H; Park SH; Kim SK
    Clin Rheumatol; 2014 Apr; 33(4):485-92. PubMed ID: 24202616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study.
    Schulman E; Bartlett SJ; Schieir O; Andersen KM; Boire G; Pope JE; Hitchon C; Jamal S; Thorne JC; Tin D; Keystone EC; Haraoui B; Goodman SM; Bykerk VP;
    Arthritis Care Res (Hoboken); 2018 Aug; 70(8):1185-1191. PubMed ID: 29193840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.
    Mariette X; Alten R; Nüßlein HG; Galeazzi M; Lorenz HM; Cantagrel A; Chartier M; Poncet C; Rauch C; Le Bars M
    Joint Bone Spine; 2017 Oct; 84(5):571-576. PubMed ID: 28043761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
    Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.
    Naniwa T; Iwagaitsu S; Kajiura M
    Int J Rheum Dis; 2018 Mar; 21(3):673-687. PubMed ID: 29314738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results.
    Lau AN; Thorne JC; Movahedi M; Rampakakis E; Cesta A; Li X; Couto S; Sampalis J; Bombardier C;
    J Rheumatol; 2019 Aug; 46(8):874-886. PubMed ID: 30988121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of physical function in early rheumatoid arthritis patients treated with biologics for 1 year who achieved clinical remission or low disease activity.
    Hattori Y; Kida D; Kaneko A
    Clin Rheumatol; 2017 Nov; 36(11):2607-2612. PubMed ID: 28823077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient.
    Pers YM; Godfrin-Valnet M; Lambert J; Fortunet C; Constant E; Mura T; Pallot-Prades B; Jorgensen C; Maillefert JF; Marotte H; Wendling D; Gaudin P
    J Rheumatol; 2015 Apr; 42(4):580-4. PubMed ID: 25641885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.
    Takahashi N; Fujibayashi T; Kida D; Hirano Y; Kato T; Kato D; Saito K; Kaneko A; Yabe Y; Takagi H; Oguchi T; Miyake H; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Hanabayashi M; Hirabara S; Asai S; Takemoto T; Terabe K; Asai N; Yoshioka Y; Ishiguro N; Kojima T
    Rheumatol Int; 2015 Oct; 35(10):1707-16. PubMed ID: 25991396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study.
    Di Carlo M; Salaffi F; Gremese E; Iannone F; Lapadula G; Ferraccioli G;
    Eur J Intern Med; 2019 Aug; 66():57-61. PubMed ID: 31113709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients.
    Iannone F; Fanizzi R; Notarnicola A; Scioscia C; Anelli MG; Lapadula G
    Joint Bone Spine; 2015 May; 82(3):187-91. PubMed ID: 25619156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions.
    Abasolo L; Leon L; Rodriguez-Rodriguez L; Tobias A; Rosales Z; Maria Leal J; Castaño V; Vadillo C; Macarron P; Fontsere O; Jover JA
    Semin Arthritis Rheum; 2015 Apr; 44(5):506-513. PubMed ID: 25532946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss Clinical Quality Management cohort.
    Vallejo-Yagüe E; Burkard T; Micheroli R; Burden AM
    BMJ Open; 2022 Sep; 12(9):e061474. PubMed ID: 36115672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables.
    Aramaki T; Kawakami A; Iwamoto N; Fujikawa K; Kawashiri SY; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Furuyama M; Matsuoka N; Ueki Y; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(6):652-6. PubMed ID: 19787419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.